Nooglutyl – 60 capsules 10mg

Nooglutyl 10 mg — 60 oral research capsules. Nooglutyl is a glutamatergic nootropic developed at the Russian Academy of Medical Sciences in the 1990s and characterized in published Russian-language pharmacology as one of the most potent positive allosteric modulators of the AMPA-type glutamate receptor in the racetam-adjacent class. Mechanistically dissimilar to the classical pyrrolidinone racetams, Nooglutyl pairs AMPA-PAM activity with glutamate-release facilitation in a way that produces robust enhancement of memory acquisition and consolidation in rodent models at sub-milligram-per-kilogram oral doses — placing it among the most pharmacologically efficient nootropic tool compounds in the published literature.

Research Overview

Nooglutyl is a glutamic-acid-conjugated heterocyclic small molecule developed at the Research Institute of Pharmacology of the Russian Academy of Medical Sciences in the late 1980s, with a substantial body of Russian-language preclinical pharmacology characterizing its memory-enhancing and neuroprotective profile [1]. Mechanistically, Nooglutyl exhibits a dual glutamatergic mechanism unusual in the nootropic literature: positive allosteric modulation of AMPA-type glutamate receptors combined with facilitation of pre-synaptic glutamate release [1,2]. In rodent models — passive-avoidance, conditioned-fear, Morris water maze, and amnesia-rescue paradigms — Nooglutyl produces robust dose-dependent enhancement of memory acquisition and consolidation at sub-milligram-per-kilogram oral doses, a potency profile substantially higher than the classical racetams [2]. The compound also displays anxiolytic, anti-amnestic and neuroprotective activity in scopolamine-induced and ischemic-injury models, with documented effects on hippocampal LTP magnitude [3]. Nooglutyl has remained an essentially Russian-research-only molecule since its original development, providing an important Eastern European entry into the AMPA-PAM cognitive-enhancement landscape that contemporary Western research is now revisiting through compounds like TAK-653 and IDRA-21.

Primary Research Areas

• AMPA-receptor positive allosteric modulation — the principal Russian-developed AMPA-PAM in the published literature; complements newer Western ampakines (IDRA-21, TAK-653) as a research comparator [1,2].
• Memory acquisition and consolidation — robust dose-dependent enhancement in passive-avoidance, conditioned-fear and spatial-memory paradigms at sub-mg/kg doses [2].
• Pre-synaptic glutamate release — the second arm of the dual mechanism, distinguishing Nooglutyl from purely post-synaptic AMPA-PAMs [1].
• Anti-amnestic and neuroprotective research — documented rescue of scopolamine-induced and ischemic-injury memory deficits in rodent models [3].
• Hippocampal LTP and synaptic plasticity — facilitates LTP induction and maintenance in hippocampal slice and in-vivo electrophysiology [1,3].

References

1. Kovalev GI, Voronina TA, Akhapkina VI, Garibova TL. Nooglutyl: profile of pharmacological activity. Eksp Klin Farmakol. 1995;58(6):3–6.
2. Voronina TA, Garibova TL, Kovalev GI. New nootropic agents and the receptor reconstruction theory of memory. Vestn Ross Akad Med Nauk. 1995;(11):14–18.
3. Voronina TA, Smirnov LD, Garibova TL. Glutamate-related nootropic and antiamnestic agents. Bull Exp Biol Med. 2009;147(5):598–602.